Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis - PubMed
a day ago
- #weight-loss
- #incretin-therapy
- #meta-analysis
- Tirzepatide and semaglutide are once-weekly injectable incretin-based agents for weight loss.
- A meta-analysis compared their efficacy, showing tirzepatide leads to greater weight reduction.
- Tirzepatide resulted in significantly higher percentage body weight reduction (-4.61%) and absolute weight loss (-4.76 kg) compared to semaglutide.
- More participants on tirzepatide achieved weight loss thresholds (≥5%, ≥10%, ≥15%, ≥20%) than those on semaglutide.
- High heterogeneity and observational data limit causal inferences, suggesting need for further research on long-term outcomes and safety.